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Abstract
Background: The Finnish Pre-eclampsia Consortium (FINNPEC) case-control cohort consisting of 1447 pre-eclamptic
and 1068 non-pre-eclamptic women was recruited during 2008–2011 to study genetic background of pre-eclampsia
and foetal growth. Pre-eclampsia was defined by hypertension and proteinuria according to the American College of
Obstetricians and Gynecologists (ACOG) 2002 classification. The ACOG Task Force Report on Hypertension in Pregnancy
(2013) and The International Society for the Study of Hypertension in Pregnancy (ISSHP) (2014) have published new
classifications, in which proteinuria is not necessary for diagnosis when specific symptoms are present. For diagnoses
based on proteinuria, the ISSHP 2014 criteria raised its threshold to 2+ on dipstick. We studied how the new
classifications would affect pre-eclampsia diagnoses in the FINNPEC cohort.
Methods: We re-evaluated pre-eclampsia diagnosis using the ACOG 2013 and the ISSHP 2014 classifications in pre-
eclamptic women whose proteinuria did not exceed 1+ on dipstick (n = 68), in women with gestational hypertension
(n = 138) and in women with chronic hypertension (n = 66).
Results: The number of women with pre-eclampsia increased 0.8 % (1459/1447) according to the ACOG 2013
criteria and 0.6 % (1455/1447) according to the ISSHP 2014 criteria. All 68 women with the amount of proteinuria
not exceeding 1+ on dipstick diagnosed originally pre-eclamptic met the ACOG 2013 criteria but only 20 women
(29.4 %) met the ISSHP 2014 criteria. Seven (5.1 %) and 35 (25.4 %) women with gestational hypertension were
diagnosed with pre-eclampsia according to the ACOG 2013 and the ISSHP 2014 criteria, respectively.
Correspondingly five (7.6 %) and 21 (31.8 %) women with chronic hypertension were diagnosed with pre-
eclampsia according to the ACOG 2 013 and the ISSHP 2014 criteria.
Conclusions: Only minor changes were observed in the total number of pre-eclamptic women in the FINNPEC
cohort when comparing the ACOC 2002 classification with the ACOG 2013 and ISSHP 2014 classifications.
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Background
Pre-eclampsia (PE) is a pregnancy-specific vascular dis-
order, the pathogenesis of which is still not completely
understood. Symptoms appear usually late in the third tri-
mester [1]. It is one of the leading causes of maternal and
neonatal morbidity and mortality. PE is characterised by
vascular endothelial dysfunction and placental implant-
ation abnormalities, causing perfusion problems and in
some cases intrauterine growth restriction [2]. PE resolves
postpartum after the delivery of the placenta. Prediction
and prevention have proven to be difficult due to the com-
plex nature of the disease [3]. There are major implica-
tions for the long-term health of the mother and the
newborn. PE is associated with elevated risk to develop
cardiovascular diseases later in life [4–6]. Affecting ap-
proximately 3-5 % of pregnancies and causing as much as
10 % of pregnancy related complications, better diagnostic
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criteria are needed to improve the recognition of PE and
its diverse subtypes.
Until the last few years, the core criteria of PE have
been considered to be a new onset hypertension after
the 20th gestational week combined with proteinuria ≥
300 mg per day. Heterogeneity of the disorder is more
and more appreciated and therefore new diagnostic cri-
teria have recently been introduced. Proteinuria has been
questioned as a sine qua non [7]. According to the two
new diagnostic criteria by The American College of Ob-
stetricians and Gynecologists (ACOG) in 2013 [8] and
International Society for the Study of Hypertension in
Pregnancy (ISSHP) in 2014 [7], new onset hypertension
in the absence of proteinuria but combined with haem-
atological complications, renal insufficiency, impaired
liver function, neurological symptoms, or uteroplacen-
tal dysfunction also fulfil diagnostic criteria for PE.
This is to provide a more broad definition of PE for
clinical practice leaving proteinuria to ensure specifi-
city of the diagnosis in scientific purposes [7]. More
sensitive recognition is beneficial considering the po-
tential severity of the disorder. Currently PE is diag-
nosed based on clinical characteristics but biomarkers
and genetic variants are expected to provide more
specific criteria in the future.
We examined how the new criteria affected the PE
diagnosis in the Finnish Genetics Pre-eclampsia Consor-
tium (FINNPEC) cohort. Originally, PE was defined by
hypertension and proteinuria according to the ACOG
2002 classification [9]. Three subgroups were re-
evaluated; PE women with the amount of proteinuria
not exceeding 1+ on dipstick, women with gestational
hypertension, and women with chronic hypertension.
Methods
FINNPEC is a nationwide database of PE and non-PE
women. At the time of writing this article on December
16, 2015, 2515 women were diagnosed (Fig. 1). Data was
collected from maternity cards and hospital records from
five university hospitals (Helsinki, Tampere, Kuopio, Oulu,
Fig. 1 FINNPEC cohort December 16, 2015. The division of FINNPEC cohort into pre-eclamptic and non-pre-eclamptic women according to the ACOG
2002 classification and the new evaluation by the ACOG 2013 and ISSHP 2014 classifications. SGA = Small for gestational age, LAB = Laboratory findings,
Subj signs = Subjective signs, PE = Pre-eclampsia
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Turku) during 2008–2011. Nulliparous or multiparous
women with a singleton pregnancy were eligible for the
study. Using the ACOG 2002 criteria, PE was defined as
hypertension and proteinuria occurring after 20 weeks of
gestation. Hypertension was defined as systolic blood
pressure ≥140 mmHg or diastolic blood pressure
≥90 mmHg after 20 weeks of gestation. Proteinuria was
defined as the urinary excretion of ≥0.3 g protein in a 24-
h specimen, or 0.3 g/l, or two ≥1+ readings on dipstick in
a random urine determination with no evidence of the
urinary tract infection. Women who suffered from pro-
teinuria without hypertension (n = 19) were included in
the control group. Furthermore, women who suffered
from gestational hypertension or chronic hypertension
but did not meet the criteria for PE were included in the
control group (n = 138 and n = 66 respectively).
Birth weights below -2.0 standard deviation (SD) units
were classified as small-for-gestational age (SGA) according
to Finnish standards (Pihkala 1989). Hemolysis, elevated
liver enzymes, and low platelet count (HELLP) syndrome
were diagnosed when at least two of the following criteria
were met: lactate dehydrogenase (LD) ≥ 235 U/l, alanine
aminotransferase (ALAT) ≥ 70 U/l, aspartate aminotrans-
ferase (ASAT) ≥ 70 U/l, thrombocytes ≤ 100 E9/l.
Each diagnosis was ascertained retrospectively based
on hospital records and confirmed independently by a
research nurse and a study physician. All subjects pro-
vided written informed consent, and the FINNPEC study
protocol was approved by the coordinating Ethics Com-
mittee of the Hospital District of Helsinki and Uusimaa.
The summary of ACOG 2013 and ISSHP 2014 criteria
is presented in Table 1. According to the two criteria, PE
is defined as hypertension combined with proteinuria, or
in absence of proteinuria, combined with at least one or
more other findings including maternal organ dysfunction
(elevated liver enzymes, haematological complications,
renal insufficiency, neurological symptoms), pulmonary
edema (ACOG 2013), and uteroplacental dysfunction
(ISSHP 2014). Hypertension is classified either as new on-
set hypertension after 20 weeks of gestation with blood
pressure levels ≥ 140/90 mmHg on two occasions at least
4 h apart, or as chronic hypertension. Some differences
appear in laboratory measurements between the two cri-
teria. Renal insufficiency is defined as creatinine levels >
100 μmol/l(1.1 mg/dL) and ≥ 90 μmol/l according to the
ACOG 2013 and ISSHP 2014 criteria respectively. A low
platelet count is defined as < 100 E^9/l and < 150 E^9/l ac-
cording to the ACOG 2013 and ISSHP 2014 respectively.
An impaired liver function is defined as elevated trans-
aminases at least twice the upper limit of normal ac-
cording to the two criteria. ACOG 2013 criteria include
pulmonary oedema and cerebral or visual symptoms in
subjective signs and present severe features of PE with
any of the following findings: blood pressure ≥ 160/
110 mmHg, thrombocytopenia < 100 E^9/l, at least dou-
bled liver enzymes, severe persistent right upper quadrant
pain or epigastric pain unresponsive to medication without
any other reason or both, progressive renal insufficiency
with at least doubled creatinine in the absence of any other
renal disease, pulmonary edema, and new-onset cerebral
and visual disturbances. ISSHP 2014 criteria include as a
sign of liver involvement severe right upper quadrant or
epigastric pain and as neurological complications e.g.,
eclampsia, altered mental status, blindness, stroke or more
commonly hyperreflexia when accompanied by clonus, se-
vere headaches when accompanied by hyperreflexia, and
persistent visual scotomata. Haematological complications
are defined as thrombocytopenia, hemolysis, and dissemi-
nated intravascular coagulation (DIC).
The most notable difference between the revised cri-
teria of ACOG and ISSHP would be in regard to the def-
inition of foetal growth restriction. ACOG defines foetal
growth restriction as a sign of severe PE according to
the 2002 criteria, but it was not included in the revised
version, whereas according to the ISSHP criteria foetal
growth restriction combined to hypertension meets the
diagnostic criteria for PE. In the present study, we con-
sidered as subjective signs severe headache, apparent vis-
ual disturbances, epigastric pain, and hyperreflexia.
Results
The number of women with PE increased 0.8 % (1459/
1447) according to the ACOG 2013 criteria and 0.6 %
(1455/1447) according to the ISSHP 2014 criteria (Figs. 1
Table 1 Summary of the PE criteria according to the ACOG
2013 and the ISSHP 2014 classifications
Pre-eclampsia criteria
ACOG 2013 ISSHP 2014
Blood pressure
≥140 mmHg systolic and/or ≥90 mmHg diastolic
Proteinuria
≥300 mg/day
urine protein/creatinine ≥30 mg/mmol
≥1+ on dipstick testing ≥2+ on dipstick testing (>1 g/l)
Or in absence of proteinuria
Liver transaminases > 2 × normal
Platelet count
PLT < 100 E9/l PLT < 150 E9/l
Renal insufficiency
Creatinine > 100 μmol/l Creatinine≥ 90 μmol/l
Subjective signs of PE
Uteroplacental dysfunction
ACOG The American College of Obstetricians and Gynecologists, ISSHP
International Society for the Study of Hypertension in Pregnancy, PLT platelet
count, PE pre-eclampsia
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and 2). The summary of the findings in women with
hypertension and proteinuria 1+ on dipstick and women
with gestational or chronic hypertension diagnosed with
PE according to the ACOG 2013 and the ISSHP 2014
classifications is presented in Tables 2, 3 and 4.
All 68 women with the amount of proteinuria not ex-
ceeding 1+ on dipstick diagnosed originally with PE met
the ACOG 2013 criteria but only 20 women (29.4 %)
met the ISSHP 2014 criteria. Of those 20 women diag-
nosed with PE according to the ISSHP 2014 criteria, 13
had abnormal laboratory measurements, four women
had an infant with growth restriction, two women had
abnormal laboratory measurements and an infant with
growth restriction, and one woman had subjective signs.
Nine women had a platelet count less than 150 E9/l but
more than 100 E9/l, five women had a platelet count less
than 100 E9/l, and eight women’s liver transaminases
were at least twice the upper limit of normal. The
woman with subjective symptoms suffered from visual
disturbances, headaches, and vivid reflexes, as well as
from twitches, nausea, and vomiting also post partum.
She had no abnormal laboratory measurements and was
treated with intravenous magnesium sulphate.
Of the 138 women with gestational hypertension ac-
cording to the ACOG 2002 criteria, seven (5.1 %) and 35
(25.4 %) women were diagnosed with PE according to
the ACOG 2013 and the ISSHP 2014 criteria respect-
ively. Of those women who met the ACOG 2013 criteria,
four women had abnormal laboratory measurements,
two women had subjective signs, and one woman had
both. Three women had a platelet count less than 100
E9/l and four women had liver transaminases twice the
normal concentration. Of those 35 women who met
the criteria of ISSHP 2014, 10 women had abnormal
laboratory measurements, 21 had an infant with
growth restriction, and one woman had both. Two
women had subjective signs and one woman had
abnormal laboratory measurements and subjective
signs. As for the abnormal laboratory measurements,
eight women had a platelet count less than 150 E9/l
but more than 100 E9/l, three women had a platelet
count less than 100 E9/l, and four women had liver
transaminases at least twice the upper limit of nor-
mal. All women with subjective signs were treated
with intravenous magnesium sulphate. Subjective
signs included epigastric pain, intense headache, visual
disturbances, and vivid reflexes. Sixty-three percent of
women with gestational hypertension who were diag-
nosed with PE according to the ISSHP criteria had an
infant with growth restriction. In addition, abnormal
laboratory findings were found more than two times
more often according to the ISSHP 2014 criteria (12)
than according to the ACOG 2013 criteria (5). This
was mainly due to low platelet counts, and six of the
women were diagnosed with PE only because of
platelet counts less than 150 E9/l.
Five (7.6 %) and 21 (31.8 %) of the 66 women with
chronic hypertension were diagnosed with PE according
to the ACOG 2013 and the ISSHP 2014 criteria, respect-
ively. Of those women who met the ACOG 2013 criteria,
2 women had abnormal laboratory findings and 3
women had subjective signs. Laboratory findings for
both women included a platelet count less than 150 E9/l
but more than 100 E9/l and liver transaminases at least
twice the upper limit of normal. Of those 21 women
who met the ISSHP 2014 criteria, 2 women had abnor-
mal laboratory findings, 15 women had an infant with
growth restriction, one woman had both abnormal la-
boratory findings and an infant with growth restriction.
One woman suffered from subjective signs, one woman
had in addition to subjective signs also abnormal labora-
tory findings, and one woman in addition to subjective
signs an infant with growth restriction. Subjective signs
of the three women included hyperreflexia, headaches,
Fig. 2 The number of women with pre-eclampsia according to the ACOG 2002 and 2013 and ISSHP 2014 classifications. Grey zone represents
women diagnosed with PE only with one of the classifications but not with the other. K = Cohen’s kappa coefficient
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epigastric pain, nausea, vomiting and visual disturbances.
Eighty-one percent of the women with chronic hyper-
tension and diagnosed with PE according to the ISSHP
criteria had an infant with growth restriction.
Four of the seven women with gestational hyperten-
sion diagnosed with PE according to the ACOG 2013
criteria had antihypertensive medication, six deliveries
were induced because of the hypertension or other
symptoms anticipating PE, and one woman underwent a
caesarean section. Two of these women gave birth be-
fore 37 + 0 weeks of gestation. Nineteen of the 35
women with gestational hypertension diagnosed with PE
according to the ISSHP 2014 criteria had antihyperten-
sive medication, 10 deliveries were induced, and 20
women underwent a caesarean section. Six women gave
birth before 34 + 0 weeks of gestation and eight before
37 + 0 weeks of gestation.
All of the five women with chronic hypertension di-
agnosed with PE according to the ACOG 2013 cri-
teria had antihypertensive medication. Two deliveries
were induced because of the hypertension or other
symptoms anticipating PE, and two women under-
went caesarean section. Three women gave birth be-
fore 37 + 0 weeks of gestation. Seventeen of the 21
women with chronic hypertension diagnosed with PE
according to the ISSHP 2014 criteria had antihyper-
tensive medication, four deliveries were induced, and
14 women underwent caesarean section. Twelve
women gave birth before 34 + 0 weeks of gestation.
Discussion
In this study, we examined how the ACOG 2013 and the
ISSHP 2014 PE classifications affected previously ascer-
tained PE diagnoses in the FINNPEC cohort defined ac-
cording to the ACOG 2002 classification. Our results
showed only minor changes in the total number of af-
fected women. There were noticeable changes within
three subgroups. All PE women with proteinuria not ex-
ceeding 1+ on dipstick remained PE according to the
ACOG 2013 criteria but less than one-third according to
the ISSHP 2014 criteria. More than one in four of the
women with gestational and chronic hypertension were
diagnosed with PE according to the revised criteria,
when proteinuria was considered optional in the pres-
ence of other findings. A challenge to the validity of the
study design is the selection of the control group (non-
PE women). Women with some symptoms and signs of
PE, which were, however, not enough to satisfy the diag-
nostic criteria, are overrepresented in the control group.
There is a need to better understand the pathophysi-
ology of PE and to define short- and long-term progno-
ses. The revised classifications by the ACOG and the
ISSHP, which change the paradigm that the diagnosis of
PE always requires proteinuria, provide broader defini-
tions of the disease, which seems justified in a heteroge-
neous disease with diverse clinical presentations. To the
best of our knowledge, this is the first study to re-
evaluate PE diagnosis according to the new classifica-
tions in a cohort of PE and non-PE women. The
strength of the study is a carefully characterised cohort
with comprehensive clinical and background informa-
tion from each study subject verified from maternity
cards and hospital records. Blood pressure and urine
measurements are performed regularly during the course
of the pregnancy in maternity clinics and documented in
maternity cards. The weakness of the study is the retro-
spective design, which may introduce biases. Ideally the
three definitions should to be applied and compared in a
population of pregnant women without any previous
Table 4 Women with chronic hypertension diagnosed with
pre-eclampsia according to the ACOG 2013 and the ISSHP 2014
criteria
ACOG 2013 ISSHP 2014
Total 5 21
SGA 17
LAB 2 4
Subjective signs 3 3
According to the ISSHP 2014 criteria, one of the women had both a SGA
newborn and abnormal laboratory findings, one woman both a SGA newborn
and subjective signs, and one woman had abnormal laboratory findings and
subjective signs
SGA small for gestational age, LAB laboratory findings
Table 2 Women with proteinuria +1 on dipstick diagnosed
with pre-eclampsia according to the ISSHP 2014 criteria
ISSHP 2014
Total 20
SGA 6
LAB 15
Subjective signs 1
Two of the women had both a SGA newborn and abnormal
laboratory measurements
Table 3 Women with gestational hypertension diagnosed with
pre-eclampsia according to the ACOG 2013 and ISSHP 2014
criteria
ACOG 2013 ISSHP 2014
Total 7 35
SGA 22
LAB 5 12
Subjective signs 3 3
One of the women had abnormal laboratory findings in addition to subjective
signs of PE according to ACOG and ISSHP criteria. One of the women had both a
SGA newborn and abnormal laboratory measurements according to ISSHP
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selection or filter. Given the incidence of PE in the gen-
eral population, to get significant results it would need a
prospective study design with a large number of unse-
lected pregnant women.
One challenge in applying retrospectively the revised
criteria is inconsistency in recording subjective signs and
symptoms, the importance of which is increased in the
diagnostic criteria of PE especially when proteinuria is
absent. Only few women had signs and symptoms that
were severe enough to be considered PE related when
proteinuria was absent or not exceeding 1+ on dipstick.
Many women had signs and symptoms weaker than the
ones defined in the revised criteria. The symptoms of
these women included transient visual disturbances,
headaches not always responding to medication but
eventually ending spontaneously, transient epigastric
sensations and pain, and vivid reflexes, albeit without
noteworthy clonus. The amount of available laboratory
measurements varies. For example, in cases where PE is
suspected late in pregnancy and delivery is warranted,
laboratory measurements might be scarce or not avail-
able. The diagnosis of PE might remain unconfirmed if
not symptomatic postpartum. Moreover, protocols of la-
boratory measurements when PE is suspected are not
harmonised between the hospitals. This might affect
how care providers react to PE symptoms when protein-
uria is absent. To minimise the bias, only one abnormal
measurement was not considered significant enough in
the present study.
In Finnish maternity care, all women with hyperten-
sion in pregnancy are carefully monitored in case of
developing proteinuria, foetal growth restriction, or
new-onset PE. Treatment of PE is still limited to antihy-
pertensive medication, eclampsia prophylaxis, and indi-
cated delivery. Identifying patients with a more broad
definition of PE does not necessarily have a major effect
to the course of the disease. When signs and symptoms
suggested PE, women are treated as if they were diag-
nosed with PE even if they did not fulfil all diagnostic
criteria. This was also seen in the FINNPEC cohort.
Women were already treated as PE patients when diag-
nosed with gestational hypertension. In some other
countries where management is more conservative for
pregnancy related hypertension, the findings may be
more relevant. Moreover, broader definitions might
provide better opportunities for earlier recognition of
PE and warrant closer observation. A more sensitive
recognition of PE might also be useful in the preven-
tion of non-communicable diseases later in life.
Women with early onset (requiring delivery before
34 weeks of gestation), recurrent, or preterm PE are
at the highest risk for cardiovascular diseases [4, 10].
However, the risk is still noticeable among all PE
women.
According to the ISSHP 2014 classification the women
included in the PE group were predominantly the ones with
foetal growth restriction. They are likely to have had more
adverse maternal and neonatal outcomes. On the other
hand, the ones excluded from the PE group were those with
minimal proteinuria and milder disease. Thus, patients di-
agnosed with PE might have more severe form of the dis-
ease. It would be interesting to see in the future studies
how maternal and neonatal outcomes change for the group
of PE patients classified by the ISSHP 2014 criteria.
For purposes of clinical practice and research, de-
mands for diagnostic criteria of PE are different. More
rigid criteria are usually applied in research, whereas in
clinical practice sensitivity is more important than speci-
ficity. Until more specific criteria are available for PE,
diagnosis relies on clinical classifications. Biomarkers
and genetic variants are candidates which are expected
to allow the refining of diagnostic and prognostic sub-
groups. Furthermore, they may clarify the role of known
risk factors, e.g., obesity and diabetes in the disease
pathogenesis. Defining better diagnostic criteria is a con-
tinuous challenge in this heterogeneous disorder. In fu-
ture, prospective studies comparing the different criteria
in a larger cohort may be appropriate to ascertain any
significant difference regarding the time of diagnosis as a
potential benefit in terms of changing managements as
well as evaluating maternal and neonatal outcomes.
Conclusion
Based on our results, the two revised classifications have
no remarkable effect on the total number of women diag-
nosed with PE in the FINNPEC cohort. The main differ-
ence between ACOG 2013 and ISSHP 2014 criteria would
be in regard to the definition of foetal growth restriction
and the amount of proteinuria. The revised classifications
of the ACOG 2013 and the ISSHP 2014 enable more sen-
sitive diagnostics of PE in women with new-onset signs
and symptoms of PE when proteinuria is absent. The new
classifications reflect the heterogeneity of PE.
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